Home
/
ANAPTYSBIO, INC
/
Financials
/
Quarterly
ANAPTYSBIO, INC — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that ANAPTYSBIO, INC filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$76.32M
Nov 4, 2025
Q2
2025
Jun 30, 2025
$22.26M
Aug 6, 2025
Q1
2025
Mar 31, 2025
$27.77M
May 5, 2025
Q3
2025
Sep 30, 2024
$30.02M
Nov 4, 2025
Q2
2025
Jun 30, 2024
$10.97M
Aug 6, 2025
Q1
2025
Mar 31, 2024
$7.18M
May 5, 2025
Q3
2024
Sep 30, 2023
$3.32M
Nov 5, 2024
Q2
2024
Jun 30, 2023
$3.46M
Aug 5, 2024
Q1
2024
Mar 31, 2023
$1.37M
May 9, 2024
Q3
2023
Sep 30, 2022
$1.29M
Nov 2, 2023
Q2
2023
Jun 30, 2022
$1.22M
Aug 7, 2023
Q1
2023
Mar 31, 2022
$970.0K
May 11, 2023
Q3
2022
Sep 30, 2021
$20.89M
Nov 8, 2022
Q2
2022
Jun 30, 2021
$30.03M
Aug 8, 2022
Q1
2022
Mar 31, 2021
$11.25M
May 4, 2022
Q3
2021
Sep 30, 2020
$0
Nov 4, 2021
Q2
2021
Jun 30, 2020
$0
Aug 9, 2021
Q1
2021
Mar 31, 2020
$15.00M
May 4, 2021
Q3
2020
Sep 30, 2019
$0
Nov 4, 2020
Q2
2020
Jun 30, 2019
$5.00M
Aug 10, 2020
Revenue (Net Sales) — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2018
Mar 31, 2018
$0
May 8, 2018
Q3
2017
Sep 30, 2017
$0
Nov 7, 2017
Q2
2017
Jun 30, 2017
$7.00M
Aug 10, 2017
Q1
2018
Mar 31, 2017
$0
May 8, 2018
Q3
2017
Sep 30, 2016
$3.21M
Nov 7, 2017
Q2
2017
Jun 30, 2016
$5.85M
Aug 10, 2017
Q1
2017
Mar 31, 2016
$4.87M
May 12, 2017
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$15.11M
Nov 4, 2025
Q2
2025
Jun 30, 2025
($38.63M)
Aug 6, 2025
Q3
2025
Jun 30, 2025
($38.63M)
Nov 4, 2025
Q1
2025
Mar 31, 2025
($39.33M)
May 5, 2025
Q2
2025
Mar 31, 2025
($39.33M)
Aug 6, 2025
Q3
2025
Mar 31, 2025
($39.33M)
Nov 4, 2025
Q3
2025
Sep 30, 2024
($32.85M)
Nov 4, 2025
Q3
2025
Jun 30, 2024
($46.66M)
Nov 4, 2025
Q2
2025
Jun 30, 2024
($46.66M)
Aug 6, 2025
Q2
2025
Mar 31, 2024
($43.94M)
Aug 6, 2025
Q1
2025
Mar 31, 2024
($43.94M)
May 5, 2025
Q3
2025
Mar 31, 2024
($43.94M)
Nov 4, 2025
Q3
2024
Sep 30, 2023
($37.31M)
Nov 5, 2024
Q3
2024
Jun 30, 2023
($39.85M)
Nov 5, 2024
Q2
2024
Jun 30, 2023
($39.85M)
Aug 5, 2024
Q1
2024
Mar 31, 2023
($44.26M)
May 9, 2024
Q2
2024
Mar 31, 2023
($44.26M)
Aug 5, 2024
Q3
2024
Mar 31, 2023
($44.26M)
Nov 5, 2024
Q3
2023
Sep 30, 2022
($33.50M)
Nov 2, 2023
Q2
2023
Jun 30, 2022
($32.55M)
Aug 7, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$34.70M
Nov 4, 2025
Q2
2025
Jun 30, 2025
($26.17M)
Aug 6, 2025
Q1
2025
Mar 31, 2025
($27.54M)
May 5, 2025
Q3
2025
Sep 30, 2024
($22.76M)
Nov 4, 2025
Q2
2025
Jun 30, 2024
($40.32M)
Aug 6, 2025
Q1
2025
Mar 31, 2024
($42.20M)
May 5, 2025
Q3
2024
Sep 30, 2023
($37.73M)
Nov 5, 2024
Q2
2024
Jun 30, 2023
($40.14M)
Aug 5, 2024
Q1
2024
Mar 31, 2023
($44.40M)
May 9, 2024
Q3
2023
Sep 30, 2022
($29.63M)
Nov 2, 2023
Q2
2023
Jun 30, 2022
($27.80M)
Aug 7, 2023
Q1
2023
Mar 31, 2022
($31.75M)
May 11, 2023
Q3
2022
Sep 30, 2021
($6.76M)
Nov 8, 2022
Q2
2022
Jun 30, 2021
($533.0K)
Aug 8, 2022
Q1
2022
Mar 31, 2021
($18.36M)
May 4, 2022
Q3
2021
Sep 30, 2020
($24.34M)
Nov 4, 2021
Q2
2021
Jun 30, 2020
($22.64M)
Aug 9, 2021
Q1
2021
Mar 31, 2020
($10.25M)
May 4, 2021
Q3
2020
Sep 30, 2019
($33.75M)
Nov 4, 2020
Q2
2020
Jun 30, 2019
($26.66M)
Aug 10, 2020